CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells - PubMed (original) (raw)
. 1993 Jun;55(6):1356-61.
Affiliations
- PMID: 8100090
CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells
P A Monach et al. Transplantation. 1993 Jun.
Abstract
To test the importance of B lymphocytes in immunity to major histocompatibility complex class I alloantigens, B cell-deficient mice were generated by reconstituting severe combined immunodeficiency mice, which lack functional B and T lymphocytes, with T cells or with both T and B cells. The reconstituted mice were challenged with a cancer that expresses an MHC class I alloantigen at a low level and is susceptible to killing by CD8+ cytotoxic T lymphocytes. Tumors grew more slowly in and were rejected more frequently by the mice lacking B cells. Understanding the mechanism by which B cells suppress tumor allograft rejection may lead to new approaches for suppressing immune attack on transplanted tissues.
Similar articles
- Beta 2M-/- knockout mice contain low levels of CD8+ cytotoxic T lymphocyte that mediate specific tumor rejection.
Lamousé-Smith E, Clements VK, Ostrand-Rosenberg S. Lamousé-Smith E, et al. J Immunol. 1993 Dec 1;151(11):6283-90. J Immunol. 1993. PMID: 8245467 - The T cell populations mediating rejection of MHC class I disparate skin grafts in mice.
Rosenberg AS. Rosenberg AS. Transpl Immunol. 1993;1(2):93-9. Transpl Immunol. 1993. PMID: 7915953 Review. No abstract available. - Cells mediating allograft rejection.
Hall BM. Hall BM. Transplantation. 1991 Jun;51(6):1141-51. doi: 10.1097/00007890-199106000-00001. Transplantation. 1991. PMID: 1675502 Review. No abstract available.
Cited by
- HER2-antigen-specific humoral immune response in breast cancer lymphocytes transplanted in hu-PBL hIL-4 NOG mice.
Ohno Y, Ohshima S, Miyamoto A, Kametani F, Ito R, Tsuda B, Kasama Y, Nakada S, Kashiwagi H, Seki T, Yasuda A, Ando K, Ito M, Tokuda Y, Kametani Y. Ohno Y, et al. Sci Rep. 2021 Jun 17;11(1):12798. doi: 10.1038/s41598-021-92311-y. Sci Rep. 2021. PMID: 34140620 Free PMC article. - Immunosuppressive Mechanisms of Regulatory B Cells.
Catalán D, Mansilla MA, Ferrier A, Soto L, Oleinika K, Aguillón JC, Aravena O. Catalán D, et al. Front Immunol. 2021 Apr 29;12:611795. doi: 10.3389/fimmu.2021.611795. eCollection 2021. Front Immunol. 2021. PMID: 33995344 Free PMC article. Review. - The tumor-promoting effects of the adaptive immune system: a cause of hyperprogressive disease in cancer?
Marcucci F, Rumio C. Marcucci F, et al. Cell Mol Life Sci. 2021 Feb;78(3):853-865. doi: 10.1007/s00018-020-03606-8. Epub 2020 Sep 17. Cell Mol Life Sci. 2021. PMID: 32940721 Free PMC article. Review. - Tumor infiltrating CD19+ B lymphocytes predict prognostic and therapeutic benefits in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors.
Lin Z, Liu L, Xia Y, Chen X, Xiong Y, Qu Y, Wang J, Bai Q, Guo J, Xu J. Lin Z, et al. Oncoimmunology. 2018 Aug 6;7(10):e1477461. doi: 10.1080/2162402X.2018.1477461. eCollection 2018. Oncoimmunology. 2018. PMID: 30288343 Free PMC article. - Secretory IgM Exacerbates Tumor Progression by Inducing Accumulations of MDSCs in Mice.
Tang CH, Chang S, Hashimoto A, Chen YJ, Kang CW, Mato AR, Del Valle JR, Gabrilovich DI, Hu CC. Tang CH, et al. Cancer Immunol Res. 2018 Jun;6(6):696-710. doi: 10.1158/2326-6066.CIR-17-0582. Epub 2018 Apr 12. Cancer Immunol Res. 2018. PMID: 29650518 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials